"JunkDNA" (98.7% of DNA in human) is not "Junk" - requiring a generalization of the "Gene concept". On http://www.junkdna.com website news items are posted (some of them reproduced here from http://www.junkdna.com/new_citations.html ) - to be discussed. My "two cents" is FractoGene (see similar website and upcoming book), a geometrization that has received now experimental support for its first prediction.

Thursday, June 30, 2005

New developments about "JunkDNA"

News items to be discussed here are compiled on http://www.junkdna.com/new_citations.html website.

This blog was created to discuss "news items" emerging in the exploding field of "JunkDNA". Hardly anybody believes that 98.7% of the (human) DNA is "Junk". The common wisdom at the moment is that it is "regulatory DNA". My "two cents" favor FractoGene, a geometrical generalization of the almost 100 year old "Gene concept". (See www.fractogene.com website, an upcoming book, experimental support of its first prediction - and a major shift in software industry for the "Post Gene Era").

Dr. Andras J. Pellionisz
http://www.usa-siliconvalley.com

Doer of "the Human Genome Project" is ready to "re-do it all"

[See posting at http://www.junkdna.com/new_citations.html ]

'Champion of "the Human Genome Project" does it again from scratch':
Venter, Launching New Company, Hopes to Synthesize Genome to Create Bacterium

NEW YORK, June 29 (GenomeWeb News) - Nearly four years after being shown the door at Celera Genomics and creating a family of nonprofits, Craig Venter has founded a new company that aims to create an organism from synthetically crafted and oriented genes.

The company, Synthetic Genomics, is in the process of building a "minimal genome" that can be inserted into the shell of a bacterium, in this case the 517-gene Mycoplasma genitalium, which scientists may eventually genetically engineer to perform specific industrial tasks.

... After designing and producing a synthetic chromosome ... the team plans to develop a proof of concept in either of two bio-energy applications: hydrogen or ethanol.

.... At a 2003 press conference announcing results from that research, Venter stressed that his team would not commercialize PCA, nor would he file patents on it. "We'd rather wait till the next stage when there's a clear-cut application: for instance if we have something that produces hydrogen that might hold some value"

Wednesday, June 29, 2005

Founders of "the Human Genome Project" are ready to "re-thinking it all"...

[See posting at http://www.junkdna.com/new_citations.html ]

Founders of "the Human Genome Project" are ready to "re-thinking it all"... The Uncertain Future for Central Dogma

The ScientistVol. 19. Issue 12, pp. 20.June 20th, 2005

The Uncertain Future for Central Dogma

Uncertainty serves as a bridge from determinism and reductionism to a new picture of biology
By Arnold F. Goodman, Claudia M. Bellato and Lily Khidr

Nearly two decades ago, Paul H. Silverman testified before Congress to advocate the Human Genome Project. He later became frustrated when the exceptions to genetic determinism, discovered by this project and other investigations, were not sufficiently incorporated in current research and education.

In "Rethinking Genetic Determinism,"1 Silverman questioned one of the pillars of molecular genetics and documented the need for determinism's expansion into a far more valid and reliable representation of reality. He would receive correspondence from all over the world that reinforced this vision.

Silverman firmly believed that we needed a wider-angled model, with a new framework and terminology, to display what we know and to guide future discovery. He also viewed this model as being a catalyst for exploring uncertainty, the vast universe of chance differences on a cellular and molecular level that can considerably influence organismal variability. Uncertainty not only undermines molecular genetics' primary pillars of determinism and reductionism, but also provides a bridge to future research.

PILLARS CHALLENGED
...
Various commentaries detail deviation from determinism within the cellular cycle. Here we use the term cellular cycle not in the traditional sense, but rather to describe the cyclical program that starts with gene regulation through transcription, translation, post-processing and back into regulation.

Richard Strohman at UC-Berkeley describes the program in terms of a complex regulatory paradigm, which he calls "dynamic epigenetics." The program is dynamic because regulation occurs over time, and epigenetic because it is above genetics in level of organization.2 "We thought the program was in the genes, and then in the proteins encoded by genes," he wrote, but we need to know the rules governing protein networks in a cell, as well as the individual proteins themselves.

John S. Mattick at the University of Queensland focuses upon the hidden genetic program of complex organisms.3 "RNAs and proteins may communicate regulatory information in parallel," he writes. This would resemble the advanced information systems for network control in our brains and in computers. Indeed, recent demonstrations suggest that RNA might serve as a genetic backup copy superseding Mendelian inheritance.4

Gil Ast of Tel Aviv University writes: "Alternative splicing enables a minimal number of genes to produce and maintain highly complex organisms by orchestrating when, where, and what types of proteins they manufacture."5 About 5% of alternatively spliced human exons contain retrotransposon Alu sequences. These elements represent an engine for generating alternative splicing.

Thus we see a genetic control system regulated by protein products, RNAs, and interventions from DNA itself. Yet throughout, the consideration of genetic uncertainty as a bridge to cellular behavior is conspicuously absent.

Genetic reductionism, the other pillar of molecular genetics, has many challengers. Among them is Stephen S. Rothman at UC-Berkeley, who described the limits of reductionism in great detail within his comprehensive and well-constructed book.6

A more recent publication by Marc H.V. Van Regenmortel at France's National Center for Scientific Research updated this assessment by discussing not only the deficiencies of reductionism, but also current ways of overcoming them. "Biological systems are extremely complex and have emergent properties that cannot be explained, or even predicted, by studying their individual parts."7

NEW CELL MODEL

Molecular genetics appears to be at a crossroads, since neither determinism nor reductionism is capable of accurately representing cellular behavior. In order to transition from a passive awareness of this dilemma to its active resolution, we must move from simply loosening the constraints of determinism and reductionism toward a more mature and representative combination of determinism, reductionism, and uncertainty.

Helen M. Blau was a keynote speaker at the recent UC-Irvine stem-cell symposium in memory of Paul Silverman and Christopher Reeve.8 She observed: "Where we look and how we look determine what we see." Although only a brief prescription, we now propose an approach to the exploration for uncertainty that involves both where we look and how we look. We examine those cellular-cycle outputs having a relatively high likelihood of diversity and its frequent companion, uncertainty.

Saturday, June 25, 2005

The Gene Concept is Dead. Long Live FractoGene!

[see article on http://www.junkdna.com/new_citations.html]

Rosetta Genomics identifies hundreds of novel human microRNAs
Medical Research News
Published: Tuesday, 21-Jun-2005


In a study published online this week and to be published as a cover story in the July issue of Nature Genetics, Rosetta Genomics' scientists report identification of hundreds of human microRNA genes, including the first report of primate specific microRNAs.
Using a novel methodology, the researchers successfully cloned and sequenced 89 human microRNAs, nearly doubling the number sequenced in man to date.
MicroRNAs are a recently discovered class of tiny regulatory genes, comprised in the 98% of the genome that does not encode proteins, which until recently were considered 'Junk DNA'. Numerous recent studies have shown microRNA genes, far from being 'junk', are in fact of central importance, regulating at least 30% of all proteins, and involved in a wide range of diseases, including diabetes, obesity, viral diseases, and various types of cancer.
"The finding of large numbers of primate specific microRNAs is exciting because it supports the notion that microRNAs may indeed play an important role in the evolution of complexity of higher organisms," said Aaron Ciechanover, Nobel prize laureate 2004, and Chairman of Rosetta Genomics' Scientific Advisory Board. "We believe that these genes may serve as an important basis for next generation diagnostics and therapeutics."
"We are extremely pleased to report our success in nearly doubling the number of human microRNAs sequenced to date, results which we believe establish Rosetta Genomics as a leading player in discovery of microRNA genes," said Isaac Bentwich MD, founder and chairman of Rosetta Genomics and lead investigator of the study. "We are now aggressively pursuing partnerships for development of diagnostics and therapeutics based on this huge group of novel microRNAs."
MicroRNAs are a recently discovered group of non-protein-coding regulatory genes, shown to be involved in a wide range of diseases in addition to neuronal and stem-cell differentiation. MicroRNAs currently are an intensely researched area, and are believed potentially to be the basis for a new class of therapeutic and diagnostic products

Friday, June 10, 2005

Behavior of Junkies determined by JunkDNA?

[for full article, see http://www.junkdna.com/new_citations.html]

Rodent Social Behavior Encoded in Junk DNA

A discovery that may someday help to explain human social behavior and disorders such as autism has been made in a species of pudgy rodents by researchers funded, in part, by the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH) and National Center for Research Resources (NCRR).

The researchers traced social behavior traits, such as monogamy, to seeming glitches in DNA that determines when and where a gene turns on. The length of these repeating sequences — once dismissed as mere junk DNA — in the gene that codes for a key hormone receptor determined male-female relations and parenting behaviors in a species of voles. Drs. Larry Young and Elizabeth Hammock, Emory University, report on their findings in the mouse-like animals native to the American Midwest in the June 10, 2005 Science.

...“This research appears to have found one of those hotspots in the genome where small differences can have large functional impact,” explained Insel. “The Emory researchers found individual differences not in a protein-coding region, but in an area that determines a gene’s expression in the brain. This is an extraordinary example of research linking gene variation to brain receptors to behavior.”

...“It was considered junk DNA because it didn’t seem to have any function,” noted Hammock.

In addition to NIH, the research was also supported by the National Science Foundation.
NIMH and NCRR are part of the National Institutes of Health (NIH), the Federal Government's primary agency for biomedical and behavioral research. NIH is a component of the U.S. Department of Health and Human Services.

Wednesday, June 01, 2005

Affy/Agilent duel - mopping up Intellectual Property

[see the original article at http://www.junkdna.com/new_citations.html ]

NEW YORK, May 31 (GenomeWeb News) -

Affymetrix said today that it plans to acquire privately held ParAllele BioScience for approximately $120 million in stock...

"The potential for ParAllele's technology goes far beyond genotyping," said Stephen Fodor, CEO of Affymetrix...

In 2003, Affy began providing its GeneChip platform for use with ParAllele's genotyping assays, which are based on its Molecular Inversion Probe technology - a process that enables up to tens of thousands of reactions to be multiplexed in a single tube.

Last year, Affy and ParAllele extended the collaboration into a distribution partnership under which ParAllele agreed to design assays for Affymetrix to market for use with the GeneChip platform. ...